Literature DB >> 11915043

Peripheral blood count abnormalities among patients with hepatitis C in the United States.

Michael B Streiff1, Shruti Mehta, David L Thomas.   

Abstract

An estimated 2.7 million people in the United States are infected with the hepatitis C virus (HCV), yet the influence of HCV infection on the peripheral blood count remains unknown. To investigate the prevalence of low peripheral blood counts among HCV-infected adults in the United States general population, we analyzed data collected in the third National Health and Nutrition Examination Survey (NHANES III). The study population consisted of 16,196 individuals age 18 or older who had peripheral blood counts and data on HCV infection. The lowest fifth percentile of each component of the peripheral blood was designated a priori as being low. HCV infection was assessed by antibody reactivity. HCV antibody-positive individuals were 3-fold more likely to have low neutrophil counts (HCV positive, 9% vs. HCV negative, 3%, P <.0001) and 2.6-fold more likely to have low platelet counts (HCV positive, 13% vs. HCV negative, 5%, P <.0001) independent of other evaluated factors. HCV infection was observed in more than 20% of persons with neutrophil counts below 1.0 x 10(9)/L or platelet counts less than 100 x 10(9)/L. No association was detected between anti-HCV status and anemia or other peripheral blood cell components. In conclusion, HCV-infected persons in the general population of the United States are more likely to have low neutrophil and platelet counts, and HCV testing should be considered for persons with unexplained neutrophil counts below 1.0 x 10(9)/L or platelet counts less than 100 x 10(9)/L. Alternate causes of anemia should be considered for HCV-infected persons with low red blood cell counts.

Entities:  

Mesh:

Year:  2002        PMID: 11915043     DOI: 10.1053/jhep.2002.32486

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  14 in total

1.  Racial differences in hepatitis C treatment eligibility.

Authors:  Michael T Melia; Andrew J Muir; Jonathan McCone; Mitchell L Shiffman; John W King; Steven K Herrine; Greg W Galler; Joseph R Bloomer; Frederick A Nunes; Kimberly A Brown; Kevin D Mullen; Natarajan Ravendhran; Reem H Ghalib; Navdeep Boparai; Ruiyun Jiang; Stephanie Noviello; Clifford A Brass; Janice K Albrecht; John G McHutchison; Mark S Sulkowski
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

2.  Clinical variables identify seronegative HCV co-infection in HIV-infected individuals.

Authors:  Ajay R Bharti; Scott L Letendre; Tanya Wolfson; David Clifford; Ann C Collier; Benjamin Gelman; Justin McArthur; Christina Marra; Allen McCutchan; Susan Morgello; David Simpson; Ron J Ellis; Igor Grant
Journal:  J Clin Virol       Date:  2011-09-15       Impact factor: 3.168

3.  Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.

Authors:  Jianping Zhang; Mita Thapar; Colm Farrell; Mary B Wire
Journal:  Pharm Res       Date:  2014-12-23       Impact factor: 4.200

4.  Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis.

Authors:  Cassidy W Claassen; Marie Diener-West; Shruti H Mehta; David L Thomas; Gregory D Kirk
Journal:  Clin Infect Dis       Date:  2012-03-28       Impact factor: 9.079

5.  Does active hepatitis C virus infection increase the risk for infection due to Staphylococcus aureus?

Authors:  A S Kaka; G A Filice; M Kuskowski; D M Musher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-03       Impact factor: 3.267

6.  Effects of Nigella sativa on outcome of hepatitis C in Egypt.

Authors:  Eman Mahmoud Fathy Barakat; Lamia Mohamed El Wakeel; Radwa Samir Hagag
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

7.  Effect of hepatic iron concentration reduction on hepatic fibrosis and damage in rats with cholestatic liver disease.

Authors:  Gil Peretz; Gabriela Link; Orit Pappo; Rafael Bruck; Zvi Ackerman
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

8.  Confluence of Epidemics of Hepatitis C, Diabetes, Obesity, and Chronic Kidney Disease in the United States Population.

Authors:  Mariana Lazo; Chizoba Nwankwo; Natalie R Daya; David L Thomas; Shruti H Mehta; Stephen Juraschek; Kerry Willis; Elizabeth Selvin
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-01       Impact factor: 11.382

9.  Trends in the prevalence of thrombocytopenia among individuals infected with hepatitis C virus in the United States, 1999-2008.

Authors:  Teresa L Kauf; David R Nelson; Jonathan Schelfhout; Joseph A C Delaney; Peter Feng Wang
Journal:  BMC Res Notes       Date:  2012-03-13

10.  Influence of chronic hepatitis C infection on the monocyte-to-platelet ratio: data analysis from the National Health and Nutrition Examination Survey (2009-2016).

Authors:  Aidan M Nikiforuk; Mohammad Ehsanul Karim; David M Patrick; Agatha N Jassem
Journal:  BMC Public Health       Date:  2021-07-13       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.